Key Highlights
- LifeMD (NASDAQ:LFMD) traded at USD 2.31 intraday on November 13, 2026, up 39.27%, on about 2.69 million shares, more than three times its average Volume of about 784,000.
- Third quarter Revenue was USD 44.6 million, down about 7% and below guidance, and full year 2026 revenue guidance was cut to USD 188 million to USD 191 million from USD 205.5 million to USD 212.5 million.
- Active subscribers rose 13% to about 350,000, Marketing spending fell by USD 9.5 million from the second quarter, and management expects roughly 30% revenue growth in 2027 on a similar Fixed Cost base.
- The shares initially fell after hours on November 12, so the Reversal into a large gain came after the earnings call, and no separate company announcement was found for November 13.
From After-Hours Drop to a Sharp Rally
LifeMD reported third quarter results after the market closed on November 12, 2026, and the first reaction was negative, with the shares down around 10% in extended trading. The headline numbers were weak: revenue of USD 44.6 million was about 7% lower than a year earlier and missed the company's own guidance, and the full year revenue range was lowered by roughly USD 16 million at the midpoint. Yet by the following session the stock had reversed sharply, rising 39.27% to USD 2.31. No new company announcement was found for November 13, so the move appears to reflect how investors weighed the commentary on the call against the reset in revenue. The largest single Factor seems to be cost discipline. Adjusted EBITDA improved by USD 3.1 million from the second quarter to a loss of about USD 0.4 million, and management said it was about halfway to cutting operating expenses by at least 25% by the first quarter of 2027. The short window between results and the rally makes this an interpretation rather than a confirmed cause.
What Management Highlighted
Several operating trends gave investors reasons for optimism. Active subscribers rose 13% from a year earlier to about 350,000. Marketing expense fell to USD 18.5 million, down USD 9.5 million from the prior quarter, and the cost to acquire a patient dropped about 40% from its June peak. Multi-month plans now account for about 85% of new weight management patients, up from about 25%, which should improve retention. Pharmacy orders rose 17% from the second quarter, and orders for compounded therapies outside the GLP-1 class tripled. The company also completed self-pay arrangements with two major makers of weight loss drugs within the last 30 days, and a membership collaboration with a large wireless carrier covering about 29 million customers in 11 states is expected to roll out nationally in January. Fourth quarter revenue guidance is USD 46 million to USD 49 million, and management said it expects about 30% growth in 2027 on roughly the same fixed overhead.
The Risks Behind the Rebound
The reset is real. The expected annualised revenue run rate at the end of 2026 is now about USD 200 million, down from an earlier target of about USD 250 million, and full year adjusted EBITDA is guided to a loss of USD 10.6 million to USD 12.6 million against a previous range of a USD 6 million loss to breakeven. Gross Margin fell to 82% from 89% as lower margin pharmacy revenue grew. Cash stood at USD 21.9 million at September 30 with no debt, and a USD 12.5 million secured term Loan was closed after the quarter, which adds funding but also leverage. LifeMD (NASDAQ:LFMD) will need to show that the 2027 growth target holds when it gives formal guidance in early January.
Where Things Stand
LifeMD rose 39.27% to USD 2.31 on November 13, 2026, reversing an after-hours drop despite a cut to 2026 revenue guidance. Investors appear to be focusing on lower costs, subscriber growth and a 30% growth target for 2027. Watch fourth quarter revenue against the USD 46 million to USD 49 million range and the January guidance.






Please wait processing your request...